HIV-1 infection in HIV-1 enzyme-linked immunoassay seronegative patients in Kinshasa, Zaire. 1990

R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
Projet SIDA, Department of Public Health, Kinshasa, Zaire.

Serum samples of 62 African patients who had clinical manifestations of HIV-1 infection but were seronegative for HIV-1 by ELISA (Organon) were subsequently further tested by another HIV-1 ELISA test (Wellcozyme), HIV-1 IgG Western blot, HIV-1 antigen detection and HIV-2 ELISA. Patients' lymphocytes were cultured for HIV-1 and 2. Because of limited quantities of serum available all tests were not performed on all samples. Seven (26%) of 27 sera of patients meeting the WHO clinical case definition of AIDS were Western-blot-positive. In contrast, of 35 patients' sera with possible HIV related disease, only one (3%) was Western blot positive (P = 0.02) and none of 75 sera from HIV-1 ELISA (Organon) seronegative blood donors (P less than 0.01) were Western blot positive. Of 30 HIV-1 ELISA (Organon) seronegative patients tested with the HIV-1 ELISA Wellcozyme assay only one was seropositive (this patient's serum was also Western blot positive). Of 17 HIV-1 ELISA (Organon) seronegative patients tested, HIV-1 antigen was found in 1 case (6%) (this patient's serum was Western blot negative). None of the 34 patients tested by HIV-2 serology was HIV-2 seropositive. HIV-1 was isolated by culture in 3 (21%) of 14 HIV-1 ELISA seronegative patients (sera of the 3 patients were Western blot negative). In total, 12 (19%) of 62 HIV-1 ELISA (Organon) seronegative patients were found to be positive for HIV, either by Western blot HIV antigen testing or viral culture.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005188 False Negative Reactions Negative test results in subjects who possess the attribute for which the test is conducted. The labeling of diseased persons as healthy when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed) False Negative Reaction,Reaction, False Negative,Reactions, False Negative
D005260 Female Females
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015023 Democratic Republic of the Congo A republic in central Africa, east of the REPUBLIC OF THE CONGO, south of the CENTRAL AFRICAN REPUBLIC and north of ANGOLA and ZAMBIA. The capital is Kinshasa. Belgian Congo,Congo (Kinshasa),Katanga,Zaire
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D015488 HIV Antigens Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens. AIDS Antigens,HIV-Associated Antigens,HTLV-III Antigens,HTLV-III-LAV Antigens,LAV Antigens,Lymphadenopathy-Associated Antigens,T-Lymphotropic Virus Type III Antigens, Human,HIV Associated Antigens,HTLV III Antigens,HTLV III LAV Antigens,Lymphadenopathy Associated Antigens,T Lymphotropic Virus Type III Antigens, Human,Antigens, AIDS,Antigens, HIV,Antigens, HIV Associated,Antigens, HIV-Associated,Antigens, HTLV III,Antigens, HTLV-III,Antigens, HTLV-III-LAV,Antigens, LAV,Antigens, Lymphadenopathy Associated,Antigens, Lymphadenopathy-Associated,Associated Antigens, HIV,Associated Antigens, Lymphadenopathy,III Antigens, HTLV

Related Publications

R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
May 1993, International journal of cancer,
R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
March 1989, World Health Organization AIDS technical bulletin,
R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
May 1991, AIDS (London, England),
R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
June 1988, Annales de la Societe belge de medecine tropicale,
R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
January 1992, Journal of acquired immune deficiency syndromes,
R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
April 1991, AIDS (London, England),
R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
December 1987, Annales de la Societe belge de medecine tropicale,
R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
January 1999, AIDS (London, England),
R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
December 1990, AIDS (London, England),
R Colebunders, and H Francis, and M M Duma, and G van der Groen, and I Lebughe, and B Kapita, and T C Quinn, and W L Heyward, and P Piot
September 1990, AIDS (London, England),
Copied contents to your clipboard!